<DOC>
	<DOCNO>NCT01025713</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability GS-9411 patient Cystic Fibrosis . GS-9411 sodium channel inhibitor , may restore airway hydration mucociliary clearance lung .</brief_summary>
	<brief_title>A Phase 1 Trial Assess Safety , Tolerability , Pharmacokinetics GS 9411 Subjects With Cystic Fibrosis ( CF )</brief_title>
	<detailed_description>GS-9411 evaluate potential therapy improve airway hydration mucociliary clearance patient cystic fibrosis . This study evaluate safety tolerability 2 dose level GS-9411 inhale product , compare match placebo .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Males female age 18 65 year Patients diagnosis CF confirm least one following : Documented sweat chloride ≥ 60 mEq/L quantitative pilocarpine iontophoresis test OR Documented sweat sodium test ≥ 60 mmol/L OR Abnormal nasal potential difference test OR At least one wellcharacterized diseasecausing genetic mutation CF transmembrane conductance regulatory ( CFTR ) gene AND Accompanying symptom characteristic CF Normal ( abnormal clinically significant ) electrocardiogram ( ECG ) Normal intraocular pressure ( IOP ) 10 21 mm Hg Screening . Normal ( abnormal clinically significant ) blood pressure ( BP ) heart rate ( HR ) absence medication hypertension ; measure subject rest supine 3 minute ; normal BP take 90 140 mm Hg systolic 50 89 mm Hg diastolic ; normal HR take 40 100 beat per minute ( bpm ) Able communicate well investigator comply requirement entire study Provision write informed consent participate show signature volunteer consent form Nonsmokers least 180 day ( 6 month ) prior Screening Must willing abstain alcohol strenuous exercise 48 hour prior Screening , 72 hour prior initial dosing , study Forced expiratory volume 1 second ( FEV1 ) ≥ 50 % predict normal age , gender , height Screening per Knudson et al Stable regimen oral CF medication , dornase alfa , physiotherapy period 28 day prior Screening ; subject take continuous ( noncycling ) inhale antibiotic prophylaxis must stable regimen drug least 90 day prior Screening Subjects must offphase cyclical inhaled antibiotic treatment regimen Must test negative hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Screening Male subject sexually active must willing use effective barrier contraception ( e.g. , condom ) heterosexual intercourse Day 1 completion study continue least 90 day date last dose study drug Male subject must refrain sperm donation Day 1 completion study continue least 90 day date last dose study drug Nonlactating female . Females hormone replacement therapy ( estrogen/progesterone ) contraceptive therapy must stabilize product dose least 90 day prior Screening Females must negative serum gonadotropin pregnancy test Screening Day 1 Nonpregnant female childbearing potential must agree use highly effective ( &lt; 1 % failure rate ) contraception heterosexual intercourse Screening , throughout study , least 30 day follow last dose study drug Glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73m2 Screening ( GFR calculate use CockcroftGault equation ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal 3× upper limit normal ( ULN ) Chest radiograph Screening without significant acute finding ( e.g. , infiltrate [ lobar diffuse interstitial ] , pleural effusion , pneumothorax ) ; chest radiograph , CT , MRI obtain within 90 day prior Screening without acute finding significant intercurrent illness ; chronic , stable finding ( e.g. , chronic scar atelectasis ) allow . A chest radiograph obtain interpreted Screening Day 1 also acceptable determine eligibility . Administration investigational drug device 28 day prior Screening A need new medication period 28 day first dose study drug , except deem principal investigator/clinical investigator interfere outcome study Subjects routinely use inhaled hypertonic saline must discontinue use least 14 day prior clinic admission duration study Use trimethoprim high dose ibuprofen ( &gt; 800 mg/day ) 28 day prior first dose Serious adverse reaction hypersensitivity drug Existence surgical medical condition , judgment clinical investigator , might interfere absorption , distribution , metabolism , excretion drug Lactating female History airway intolerance hypertonic saline History lung transplantation History positive test Burkholderia cepacia History cirrhosis ascites History clinically significant adrenal disease History congestive heart failure diagnose clinically document leave ventricular ejection fraction ( LVEF ) ≤ 40 % History glaucoma Consumption drug and/or herbal preparation capable induce hepatic enzyme metabolism ( e.g. , barbiturate , rifampicin , carbamazepine , phenytoin , primidone , St. John 's Wort ) within 28 day ( 5 halflives induce agent , whichever long ) Screening Subjects require follow drug 28 day prior Screening : diuretic ( e.g. , spironolactone , amiloride , thiazide ) , ACE inhibitor , angiotensin receptor blocker , oral corticosteroid , medicine hypertension Donation loss great 400 mL blood period 90 day ( 3 month ) prior Screening Major surgery within 180 day ( 6 month ) Screening Hemoglobin level &lt; 120 g/L female &lt; 130 g/L male take Screening Day 1 Serum potassium &gt; 5 mEq/L take Screening Day 1 Poor venous access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>Mucociliary Clearance</keyword>
	<keyword>Epithelial Sodium Channel Inhibitor</keyword>
	<keyword>ENaC Inhibitor</keyword>
	<keyword>Airway Hydration</keyword>
	<keyword>Amiloride</keyword>
</DOC>